Medtronic acquiring Contego Medical for $380M to expand its vascular portfolio
Medtronic has agreed to acquire Contego Medical, the North Carolina-based medtech company known for its vascular and endovascular devices, in a deal valued at approximately $380 million.
These two companies have already been working together for quite some time. Medtronic first invested in Contego Medical in 2020. And in January 2025, the medtech giant agreed to be the exclusive U.S. distributor of Contego Medical’s devices for carotid and peripheral vascular disease revascularization. That agreement increased Medtronic’s investment and gave the company the option to acquire Contego Medical in full at a later date.
“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” David Moeller, senior vice president and president of Medtronic’s peripheral vascular health division, said in a statement. “By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularization.”
“Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter,” added Ravish Sachar, MD, founder and CEO of Contego Medical. “We're proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients.”
This acquisition comes just days after Contego Medical received updated approvals from the U.S. Food and Drug Administration (FDA) for its Neuroguard IEP Direct System and Neuroguard IEP Embolic Protection System to be used for the treatment of narrowed carotid arteries. These devices, which first secured FDA approval in October 2024, are intended to reduce the risk of stroke when treating carotid artery lesions.
Medtronic is working to finalize this transaction by the third quarter of its fiscal year. The deal may include additional payments after the initial acquisition.

